Digital Health Investment Weekly Report Vol.166: Global Funding Highlights and Industry Moves

Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry第一时间!

01 Global Digital Health Investment and Financing Overview

Drug Delivery Platform Developer SpyGlass Pharma Secures $75 Million in Series D Funding

On June 3, SpyGlass Pharma, a developer of drug delivery platforms, secured $75 million in Series D funding led by Sands Capital with participation from Gilde Healthcare. Existing investors NEA, RA Capital, Vensana Capital, Samsara BioCapital, and Vertex Ventures HC continued their support. The funds will be used to advance the development of its long-acting drug delivery platform, particularly for the long-term treatment of glaucoma and other chronic ophthalmic diseases.

Empathy, a one-stop care platform for the elderly, raises $72 million in Series C funding

On May 29, Empathy, a one-stop senior care platform, secured $72 million in Series C funding led by Adams Street Partners, with participation from General Catalyst, Index Ventures, and others. The funds will be used to accelerate product innovation and further expansion while officially establishing the Empathy Alliance.

Healthcare Fintech Platform Provider Paytient Secures $40 Million in Financing

On June 4, Paytient, a financial technology platform provider for healthcare, secured $40 million in funding from Trinity Capital. This round of financing will be used to expand its payment solutions to cover large group employer-sponsored plans, alternative health plans, ACA marketplaces, and Medicare, promoting affordability or cost-smoothing solutions for out-of-pocket expenses as a standard benefit of health plans.

Drug Discovery Platform Developer Vivodyne Secures $40 Million in Series A Funding

On May 29, Vivodyne, a drug discovery platform developer, secured $40 million in Series A funding led by Khosla Ventures with participation from Lingotto Investment Management and others. The funds will be used to expand the scale of testing using its robotics + artificial intelligence technology on thousands of lab-grown human tissues and to open a new 23,000-square-foot fully robotic laboratory in San Francisco to meet the needs of global pharmaceutical clients.

Medical Aesthetics R&D Company Acclaro Medical Secures $23 Million in Series B Funding

On May 29, Acclaro Medical, a medical aesthetics R&D company, secured $23 million in Series B funding led by Accelmed Partners, with participation from existing investor 3E Bioventures Capital. The proceeds will be used to accelerate the growth of its flagship products UltraClear® and AuraLux™, expedite global market expansion, and drive the development of new groundbreaking products in its R&D pipeline.

Breast Cancer Treatment Platform Developer Outcomes4Me Secures $21 Million in Financing

On May 29, Outcomes4Me, a developer of breast cancer treatment platforms, secured $21 million in funding, led by Salica Investments of London, with participation from existing investors Labcorp Venture Fund, Forecast Labs, and others. The funds will be used to accelerate the development of its AI-driven patient empowerment platform, assisting cancer patients in adopting proactive approaches from diagnosis through every stage of life and care.

Canid, a provider of end-to-end platforms for vaccine automation and management, secures $10 million in Series A funding

On June 3, Canid, a provider of end-to-end platforms for vaccine automation and management, secured $10 million in Series A funding led by Telescope Partners, with participation from FJ Labs, Brooklyn Bridge Ventures, and SeedtoB. The funds will be used to drive the company’s expansion plan to serve the growing number of independent pediatricians in the United States.

Dry Powder Inhalation Formulations, Inhalation Devices, and Related Equipment Developer Yihe Medicine Secures Nearly 50 Million Yuan in A+ Round Financing

On June 3, Yeehong Pharmaceutical, a developer of dry powder inhalation preparations, inhalation devices, and related equipment, secured nearly 50 million yuan in an A+ funding round, led by Zhang…State CircleShan Fund and Beijing Yishang Huicheng Joint Investment. This round of financing will be used to accelerate the commercial scale-up of inhalation health products, advance the clinical validation of core products, and upgrade the world-leading dry powder inhalation formulation technology platform, helping the company build competitive barriers in the billion-level inhalation formulation market.

Dobot Technology and Yishi Bang Reach Strategic Cooperation, Focusing on Pharmaceutical Collaborative Robots and Intelligent Solutions

On June 3, Dobot Technology and Yaoshi Bang signed a strategic cooperation agreement, deciding to establish a comprehensive strategic partnership. Focusing on pharmaceutical embodied intelligent robots, AI large models, and pharmaceutical IoT technologies, they will jointly explore the application of smart solutions in the entire chain of scenarios including pharmaceutical R&D, warehousing, distribution, retail, and medication services.

QIAGEN Collaborates with Foresight and Tracer to Develop MRD Detection Products

On June 2, QIAGEN entered into collaborations with Foresight Diagnostics and Tracer Biotechnologies to develop minimal residual disease (MRD) detection products based on NGS and digital PCR, respectively. This collaboration will cover lymphoma, other malignancies, and solid tumors, reinforcing QIAGEN's leadership in the oncology field. QIAGEN will integrate Foresight’s Clarity MRD liquid biopsy technology to develop an NGS-based MRD detection kit for lymphoma and other malignancies, and utilize Tracer’s QiAcuity digital PCR platform to develop MRD companion diagnostic products for solid tumors.

Behavioral Health Provider Lucet Acquires Emcara Health

On June 3, behavioral health company Lucet acquired Emcara Health, a national value-based healthcare group and provider of home medical care services. This strategic acquisition aims to address the growing demand for integrated care models, effectively managing chronic physical conditions and mental health needs associated with comorbidities. Lucet’s long-term strategy focuses on continuous growth, identifying gaps in products and services to meet the comprehensive health needs of its members. Through this acquisition, Lucet will be able to offer a more holistic approach to care, assess mental health needs, and quickly connect individuals with high-quality healthcare resources.

Clinical Technology and Evidence-Based Solutions Provider Wolters Kluwer Health Acquires IntelliLearn

On May 30, Wolters Kluwer Health, a provider of clinical technology and evidence-based solutions, acquired IntelliLearn, an online nursing education solutions provider. IntelliLearn primarily offers online course solutions to nursing schools in Australia and the United States. This acquisition will make IntelliLearn part of Wolters Kluwer Health's Health, Learning, Research & Practice (HLRP) business, a recognized leader in nursing education and practice solutions. By integrating IntelliLearn’s specialized content into the Lippincott suite of nursing products, Wolters Kluwer will expand its range of training modules designed for nursing students.

AI-Driven Genomics and Personalized Health Platform Mapmygenome Acquires Microbiome Insights

On May 29, Mapmygenome, an AI-driven genomics and personalized health platform, acquired Microbiome Insights, a provider of microbiome sequencing services. The acquisition includes Microbiome Insights' CAP-certified Canadian laboratory and its extensive intellectual property, further enhancing Mapmygenome's scientific capabilities and advancing its global expansion. Microbiome Insights will continue to operate as a leading contract research organization driving global research, while Mapmygenome will launch its integrated genomics and microbiome testing services, making holistic, data-driven health solutions more accessible.

ArteryNet/Arterial Orange Industry Think Tank/China Renaissance/BGI Co-Win/Rock Health/Mobile Health News/FierceHealth, etc.

Compiled by: Hou Zhancan, Huang Changjian‍‍‍

Share

Like

Click to view